eGenesis-cover-image

eGenesis is advancing genetically engineered porcine organs for human transplant. The company’s lead product (EGEN-2784) is for the treatment of patients with kidney failure. eGenesis has published the most extensive preclinical dataset in the field of cross-species transplantation, demonstrating consistent and durable long-term survival. In March 2024, the company’s lead product was used in the world’s first porcine kidney transplant in a living human patient. eGenesis is also advancing additional programs for patients with heart failure, liver failure.

Nulla adipisicing do ut aliquip elit tempor fugiat. Mollit est exercitation excepteur ea consequat ullamco Lorem ex id. Ipsum nostrud Lorem dolor nisi do est in ex amet eu nostrud. Amet commodo consectetur enim nostrud dolore sint excepteur irure aliqua consectetur. Veniam occaecat et enim eiusmod qui fugiat eiusmod eiusmod laborum exercitation veniam ipsum velit. Ut veniam cupidatat ea tempor ad ad exercitation amet qui. Esse commodo sint deserunt ut elit minim sint. Amet laborum ut adipisicing minim sunt cillum anim in est ipsum aliquip anim in tempor pariatur.

industries

Advancing Human Health

Biology Biochemistry

Milestones

Lux investment: 2024

Founders

George Church

Luhan Yang

Lux partners
Peter Hébert

eGenesis

David Yang
Kim Tran
Tess van Stekelenburg
Andrew Wilson
Tracie Rotter
Stevie Lee
Steven Brody
Shaq Vayda
Shahin Farshchi, PhD
Segolene Scarborough
Sean Traynor
Scott Rubin
Saunaz Moradi
Samuel Arbesman, PhD
Samantha Cho
Peter Hébert
Lindsay Morris
Lan Jiang
Josh Wolfe
Grace Isford
Deena Shakir
Debbie Elsen
Danny Crichton
Cristina Morris
Bree Morgan
Brandon Reeves
Brad Gritsch
Bilal Zuberi
Bibi Masara
Alex Nguyen
Adam Kalish